ID Week 2022

Vilobelimab is a monoclonal antibody which works to reduce the level of complement split factor C5a by preserving the membrane attack complex.

Patients with COVID-19 who required low-flow oxygen supplementation were randomly assigned to receive either SNG001 (n=314) or placebo (n=309) once daily for 14 days.

The MVA-BN vaccine, developed by Bavarian Nordic, was evaluated in a clinical trial.

Among 140 patients included in the analysis, 56.4% had serum procalcitonin levels of less than 0.5 ng/mL, while 43.6% had levels of 0.5 ng/mL or higher.

Researchers evaluated the accuracy of the BV score using data from pediatric patients with fever who presented at emergency departments or urgent care centers.

A total of 1428 patients were included in the analysis, of whom 185 (13%) were vaccinated and 1243 (87%) were unvaccinated against COVID-19 infection.

Bacterial culture growth was reported in 13 (14%) patients, and 5 (5%) had urinary tract or bloodstream infections.

The researchers aimed to describe the clinical profile of IED, as well as the pattern of AMR for causative E coli isolates.

Rate of decolonization was highest for patients in the EGD group (85.7%), followed by those in the oral capsule (84.6%), colonoscopy (63.6%), and gastric tube (50%) groups.

During a median follow-up period of 73 (range, 13-111) weeks, 1 patient discontinued treatment with lenacapavir due to grade 1 nodule at the injection site.